Chen Chung-Ho, Tsai Tsung Lin, Yang Yi-Shin, Tsai Chi-Cheng
Department of Oral Maxillofacial Surgery, Chung-Ho memorial Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
J Oral Pathol Med. 2007 Feb;36(2):83-7. doi: 10.1111/j.1600-0714.2007.00502.x.
Over-expression of HER-2/neu has been associated with advanced disease, metastasis, and poor clinical outcome. Squamous cell carcinoma (SCC)-related antigen (SCCA) is used as a tumor marker in a variety of SCC. This study was performed to investigate the pre- and post-treatment values of HER-2/neu and SCCA in patients with oral SCC.
Patients with OSCC were enrolled between 2002 and 2004. Serum samples were obtained before treatment and at 1 month following treatment. HER-2/neu levels and SCCA levels were determined by enzyme-linked immunosorbent assay and radioimmunoassay, respectively.
A significant correlation was found between HER-2/neu and lymph node metastasis (P = 0.0252). SCCA correlated with tumor size (P = 0.0042). Both HER-2/neu and SCCA mean levels were reduced significantly after treatment.
The combination of HER-2/neu and SCCA serum levels may be a useful marker in evaluating therapeutic effects and in monitoring the recurrence rate of OSCC and survival rate of patients.
HER-2/neu的过表达与疾病进展、转移及不良临床预后相关。鳞状细胞癌（SCC）相关抗原（SCCA）在多种SCC中用作肿瘤标志物。本研究旨在调查口腔SCC患者治疗前后HER-2/neu和SCCA的值。
2002年至2004年纳入口腔鳞状细胞癌患者。在治疗前和治疗后1个月采集血清样本。分别通过酶联免疫吸附测定和放射免疫测定法测定HER-2/neu水平和SCCA水平。
发现HER-2/neu与淋巴结转移之间存在显著相关性（P = 0.0252）。SCCA与肿瘤大小相关（P = 0.0042）。治疗后HER-2/neu和SCCA的平均水平均显著降低。
HER-2/neu和SCCA血清水平的联合可能是评估治疗效果、监测口腔鳞状细胞癌复发率和患者生存率的有用标志物。
